AAA
CTMX icon

Affinity Asset Advisors’s CytomX Therapeutics CTMX Stock Holding History

Affinity Asset Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-125,000
Closed -$636K – 59
2021
Q3 		$636K Buy
125,000
+50,000
+67% +$268K 0.16% 66
2021
Q2 		$475K Buy
75,000
+25,000
+50% +$195K 0.17% 65
2021
Q1 		$387K Buy
+50,000
New +$396K 0.13% 68

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Affinity Asset Advisors's CTMX Position: Q4 2021 in Review

Affinity Asset Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 125,000 shares — an estimated $636K sold.

Affinity Asset Advisors first reported a position in CTMX in Q1 2021 and held it in 3 quarters. The position peaked at $636K in Q3 2021. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

  • Affinity Asset Advisors reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 125,000 CytomX Therapeutics shares in Q4 2021, an estimated $636K.
  • Affinity Asset Advisors first reported a position in CytomX Therapeutics in Q1 2021 and held it in 3 quarters.
  • Affinity Asset Advisors's CytomX Therapeutics position peaked at $636K in Q3 2021.
  • 110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.